Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Key facts

Sponsor

Karyopharm Therapeutics Inc

Intervention

Selinexor(drug)

Enrollment

244 enrolled

Eligibility

18 years · All sexes

Timeline

2014 – 2027

Study locations (30)

• UACC Arizona, Tucson, Arizona, United States
• University of California San Francisco, San Francisco, California, United States
• University of California Los Angeles (UCLA), Santa Monica, California, United States
• Boca Raton Cancer Research Medical Center, Plantation, Florida, United States
• University of Chicago, Chicago, Illinois, United States
• Robert H. Lurie Comprehensive Cancer Center/Northwestern University, Chicago, Illinois, United States
• Norton Cancer Institute, Louisville, Kentucky, United States
• Dana Farber Cancer Institute, Boston, Massachusetts, United States
• Tufts Medical Center, Boston, Massachusetts, United States
• Lahey Clinic, Burlington, Massachusetts, United States
• University of Massachusetts Medical School, Worcester, Massachusetts, United States
• John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
• Clinical Research Alliance, Lake Success, New York, United States
• New York Presbyterian Hospital/ Cornell Medical College, New York, New York, United States
• Stony Brook University Hospital, Stony Brook, New York, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Diffuse large B-cell lymphoma with chronic inflammation

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT07538180
  Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL
  Sun Yat-sen University
• RECRUITINGNCT07070648
  Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
  Fudan University
• RECRUITINGPHASE1, PHASE2NCT06829771
  Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
  Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• RECRUITINGPHASE3NCT06717347
  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE2NCT06687772
  CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
  Washington University School of Medicine
• RECRUITINGPHASE1, PHASE2NCT06760039
  Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
  Sun Yat-sen University
• RECRUITINGPHASE2NCT06701357
  CR-CHOP+X in Previously Untreated DEL
  Ruijin Hospital
• RECRUITINGPHASE2NCT06664411
  Pola-ZR2P in Previously Untreated DLBCL
  Navy General Hospital, Beijing

See all trials for Diffuse large B-cell lymphoma with chronic inflammation →